The following claims are presented for examination:

1. (currently amended) A drug delivery device comprising: a drug; and a vascular implant having a blood-contacting surface and a helical formation on the blood contacting surface, the helical formation **having a helix angle of between 8° and 20° and** being capable of inducing helical flow of blood flowing past the helical formation, and the drug being releasably associated with the helical formation of the vascular implant.

2. (original) A drug delivery device according to claim 1 wherein the drug is mixed into the material from which the helical formation is made.

3. (previously presented) A drug delivery device according to claim 1 wherein the drug is coated onto the surface of the helical formation.

4. (previously presented) A drug delivery device according to claim 1 wherein the helical formation is made from a polymer.

Claims 5-16 (canceled)

17. (previously presented) A drug delivery device according to claim 4 wherein the polymer is a polymer foam.

18. (previously presented) A drug delivery device according to claim 4 wherein the polymer is selected from the group consisting of: polyamide, polyester, and polyurethane.

19. (previously presented) A drug delivery device according to claim 4 wherein the drug is bound onto the cellular structure of the polymer.

20. (previously presented) A drug delivery device according to claim 1 wherein the drug is selected from the group consisting of: an anticoagulant, an antiplatelet agent, an angiogenesis inhibitor, a cyclooxygenase inhibitor, a gene therapy agent, and a mixture of two or more of said drugs.

21. (previously presented) A drug delivery device according to claim 1 wherein the vascular implant is selected from the group consisting of: an intravascular stent insert, a vascular graft, and a stent graft.

22. (previously presented) A drug delivery device according to claim 21 wherein the vascular implant is a stent and the drug delivery device further comprises a sleeve positioned surrounding and/or within the stent.

23. (previously presented) A drug delivery device according to claim 22 wherein the sleeve is made from expanded PTFE.

24. (previously presented) A drug delivery device according to claim 1 wherein the drug is also releasably associated with the blood-contacting surface of the vascular implant.

25. (previously presented) A drug delivery device according to claim 1 wherein at least one further drug is provided releasably associated with the helical formation.

26. (canceled)

27. (previously presented) A drug delivery device according to claim 1 wherein the helical formation comprises at least one fin.

28. (previously presented) A drug delivery device according to claim 27 wherein the at least one fin has the shape of a right-angle triangle in cross-section.

29. (previously presented) A drug delivery device according to claim 27 wherein the at least one fin has the shape of an isosceles triangle in cross-section.

30. (previously presented) A drug delivery device according to claim 27 where the at least one fin has the shape of a bell in cross-section.

31. (previously presented) A drug delivery device according to claim 30 where the at least one fin has the shape of an asymmetric bell in cross-section.

32. (previously presented) A drug delivery device according to claim 1 wherein the helical formation comprises a groove.